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Adjunctive Lurasidone Suppresses Food Intake and Weight Gain 
Associated with Olanzapine Administration in Rats
Gavin P. Reynolds1, Caroline F. Dalton1, William Watrimez2, Joshua Jackson2, Michael K. Harte2
1Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, 2Division of Pharmacy and Optometry, School of Health 
Sciences, Manchester, UK
Objective: Lurasidone is an antipsychotic drug that shows a relative lack of weight gain common to many antipsychotics. 
Aripiprazole and ziprasidone also show little weight gain and can reduce olanzapine-induced food intake and weight 
gain in animals, paralleling some clinical findings. We hypothesized that lurasidone would have similar actions.
Methods: Female Lister-hooded rats received intraperitoneal injection either 2× vehicle (saline), lurasidone (3 mg/kg) 
and vehicle, olanzapine (1 mg/kg) and vehicle, or olanzapine and lurasidone. Following drug administration food intake 
was measured for 60min. A further series of rats underwent a seven-day regime of once-daily administration of the 
above doses and free access to food and water. Weight gain over the course of the study was monitored. 
Results: Olanzapine induced a significant increase in food intake while lurasidone showed no significant effect. Co-ad-
ministration of lurasidone with olanzapine suppressed the increase in food intake. Repeated dosing showed an increase 
in body weight after seven days with olanzapine, and no significant effect observed with lurasidone, while repeated 
administration of lurasidone with olanzapine reduced the effect of olanzapine on the increase in body weight. 
Conclusion: These findings support our hypotheses in that lurasidone, in addition to a lack of effect on acute food 
intake and short term weight gain, can reduce olanzapine-induced food intake and weight gain in rats. This indicates 
the drug to have an active anti-hyperphagic mechanism, rather than solely the absence of a drug-induced weight gain 
that is such a severe limitation of drugs such as olanzapine.
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INTRODUCTION
Many antipsychotic drugs demonstrate adverse effects 
on body weight and metabolic syndrome, primarily a 
clinically significant weight gain emerging within 6 weeks 
of initial treatment in many subjects.1) Among the com-
monly-prescribed antipsychotic drugs, clozapine and 
olanzapine exhibit the greatest weight gain. However an-
tipsychotic-induced weight gain is not restricted to sec-
ond-generation drugs; furthermore, some antipsychotics 
induce negligible weight gain. A recent multi-comparison 
meta-analysis indicated that only haloperidol, ziprasi-
done, and lurasidone did not differ from placebo levels of 
weight gain, while these drugs, along with aripiprazole, 
had significantly less weight gain than quetiapine and ris-
peridone, which in turn show significantly less weight 
gain than olanzapine.2)
We and others have demonstrated that the weight gain, 
which reflects increased food intake, occurring in patients 
receiving olanzapine can be reliably modelled in the rat 
in acute effects on food intake and satiety and both short 
and longer term effects on body weight.3,4) We have also 
found that ziprasidone can reverse the hyperphagic effect 
of olanzapine.3) This indicates that ziprasidone has a 
pharmacological action that goes beyond a lack of olan-
zapine-like hyperphagia to include an additional pro-
tective component. We see the same effect with aripipra-
zole5) and have proposed that a partial agonist/antagonist 
action at the 5-HT1A receptor of ziprasidone and aripi-
prazole may be one mechanism that could contribute to 
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Fig. 1. Food intake over 60 minutes following drug administration.
*p＜0.05 vs. vehicle; †p＜0.05 vs. olanzapine.
Fig. 2. Weight gain over 7 days of drug administration.
*p＜0.05 vs. no olanzapine; †p=0.10 vs. olanzapine.
these findings, although other pharmacological effects 
may be important.6) The results have implications in the 
clinic: it has been observed that aripiprazole can amelio-
rate weight gain and some other metabolic changes in pa-
tients receiving olanzapine7) or clozapine.8)
The current study was to determine whether this pro-
tective mechanism against olanzapine-induced food in-
take and weight gain extends to lurasidone, given that this 
drug too has effects at the 5-HT1A receptor and in clinical 
trials has been shown to be relatively free of a propensity 
for weight gain.2) We specifically tested the hypotheses 
that co-administration of lurasidone would suppress the 
acute increase in food intake following olanzapine ad-
ministration to rats, and would also suppress the short 
term (one week) weight gain seen following daily admin-
istration of olanzapine.
METHODS
Adult female Lister hooded rats housed under standard 
laboratory conditions with a 12-hour cycle (lights on at 
7:00) were habituated to the experimental procedure in 
individual cages with a palatable mash food preparation5) 
for 4 days prior to the test day. The day before the test day 
all animals received a saline injection prior to injections 
on the test day. On the test day all animals were put in the 
test cages and given 30 minutes access to the mash (initial 
food intake). They were then removed and given the ap-
propriate injections; four groups of six animals received 
either 2× vehicle (saline), lurasidone (3 mg/kg, intra-
peritoneal injection) and vehicle, olanzapine (1 mg/kg, 
intraperitoneal injection) and vehicle, or olanzapine and 
lurasidone. Drug doses were chosen based on our prior 
experience with olanzapine in inducing weight gain4) and 
the effective dose of lurasidone in an animal model of an-
tipsychotic efficacy.9) Following drug administration all 
animals were returned to the cages with the food for a fur-
ther 60 minutes (final food intake). Weight of initial and fi-
nal food intake was measured.
A further series of rats underwent a seven-day dosing 
regime in the above groups of six animals each, receiving 
once-daily administration of the above doses. Animals 
had free access to food and water. Prior to each dose the 
animals were weighed, and weight gain over the course of 
the study was monitored. All experiments were performed 
according to the Animals (Scientific Procedures) Act 
1986, and with approval from the University of 
Manchester Research Ethics Committee. 
Initial statistical analysis was undertaken by analysis of 
variance using IBM SPSS Statistics ver. 21.0 (IBM Corp., 
Armonk, NY, USA) followed post-hoc by Dunnett’s t test.
RESULTS
The results of the initial acute study are indicated in 
Figure 1. Analysis of variance demonstrated a significant 
overall effect (F=3.818, p=0.027). There is a significant 
increase in food intake with olanzapine (p=0.031 vs. ve-
hicle) in the absence of any significant effect of lurasidone 
administration. Notably, co-administration of lurasidone 
with olanzapine suppresses the increase in food intake 
seen with the latter drug (p=0.043 vs. olanzapine).
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The short term dosing study (Fig. 2) showed the same 
pattern of results, although the overall effect was not sig-
nificant (F=1.652, p=0.209). Nevertheless, further ex-
ploratory analysis showed an increase in body weight 
over control and lurasidone animals after seven days’ ad-
ministration of olanzapine (p=0.031), with no mean in-
crease observed with lurasidone. Furthermore, the re-
peated administration of lurasidone with olanzapine 
showed an apparent reduction in the effect of olanzapine 
administration alone on the increase in body weight, al-
though this did not achieve statistical significance (p= 
0.10 vs. olanzapine).
DISCUSSION
These preliminary findings clearly support our initial 
hypotheses in showing that lurasidone, in addition to 
demonstrating a lack of effect on acute food intake in 
clear contrast to olanzapine, also demonstrates a pro-
tective effect on olanzapine-induced food intake in rats. 
Similar effects were observed in the short-term weight 
gain study, although the findings did not achieve stat-
istical significance. This apparently protective mecha-
nism on food intake has also been demonstrated for aripi-
prazole and ziprasidone, indicating that the three drugs 
have an active anti-hyperphagic mechanism, rather than 
solely the absence of the pharmacological propensity for 
weight gain and which is such a severe limitation of drugs 
such as olanzapine.
This study is both small and short-term and thus would 
benefit from replication and extension in both size and 
time course. The weaker effects on weight gain that we 
observed reflected the presence of a single animal in the 
olanzapine group that showed minimal (3 g) weight gain 
in comparison to a range of 7 to 12 g for the other rats re-
ceiving olanzapine. Nevertheless these findings indicate 
the value of investigating whether there might be a benefi-
cial effect of adjunctive lurasidone in the amelioration 
and/or attenuation of antipsychotic-induced weight gain, 
an effect that is clinically well established for aripipra-
zole.10) We have used female animals since in our experi-
ence they more readily demonstrate antipsychotic-induced 
weight gain than males; this observation has been dis-
cussed previously.4)
Current understanding of the pharmacological mecha-
nism(s) underlying weight gain following antipsychotic 
drug treatment is far from complete. We found olanza-
pine-induced weight gain can be effectively modelled in 
the short term by a combination of a D2 antagonist 
(haloperidol) and a 5-HT2C inverse agonist, but not by a 
D2 and histamine H1 antagonist combination.4) Thus one 
contributory process may be the action of drugs on hypo-
thalamic neurotransmitter receptors including, but not 
necessarily exclusively, the 5-HT2C receptor, which is 
likely to disrupt signalling from hormones such as leptin.6) 
This concept provides a good model for understanding 
some effects of drugs with high metabolic risk such as 
olanzapine, although it may not fully account for the in-
termediate effects of some other antipsychotic drugs2) for 
which other receptors including histamine H1 may be 
important. Certainly serotonin neurotransmission has an 
important role in the regulation of food intake and body 
weight and thus drugs acting at 5HT receptors may influ-
ence these processes. One other receptor important in 
eating behaviour is the 5-HT1A site11); this can modulate 
presynaptic neuronal activity as well as having post-
synaptic action. 5-HT1A and 5-HT2C receptors have op-
posite effects on body weight, and the 5-HT1A partial 
(ant)agonism of lurasidone, as we have suggested for zi-
prasidone and aripiprazole,6) may contribute to inhibiting 
orexigenic effects of antipsychotics, such as olanzapine 
and clozapine, that have strong 5-HT2C inverse 
agonism.12) This hypothesis has yet to be tested, however.
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